(S)-2-(4-(4-(4-(5-(1-amino-1-(4-fluorophenyl)ethyl)pyrimidin-2-yl)piperazin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl)-1H-pyrazol-1-yl)ethan-1-ol free base · Synonyms: 2505078-08-8
A tyrosine kinase inhibitor.
For research use only. Not for human or veterinary use.
Purity >98%
Stock Inquire
(S)-2-(4-(4-(4-(5-(1-amino-1-(4-fluorophenyl)ethyl)pyrimidin-2-yl)piperazin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl)-1H-pyrazol-1-yl)ethan-1-ol structure
CAS No.: 2505078-08-8
Pack sizes & pricing
Description
A tyrosine kinase inhibitor.
Biological activity
BLU 263, is a next-generation tyrosine kinase inhibitor (KIT) being developed by Blueprint Medicines for the treatment of indolent systemic mastocytosis (SM).
Identifiers
- SMILES
-
OCCN1C=C(C=N1)C2=CN3N=CN=C(N4CCN(C5=NC=C([C@@](N)(C6=CC=C(C=C6)F)C)C=N5)CC4)C3=C2 - InChIKey
-
IPMARPMXSFFZFG-MHZLTWQESA-N
Specifications
- MW (average)
- 528.5840
- Formula
- C27H29FN10O
- CAS No.
- 2505078-08-8
- Physical state
- Solid
- Color
- white to off-white
- Shipping
- Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
- Storage
- Powder -20℃ 2 years; In solvent -20℃ 1 month;
Solubility
Soluble in DMSO
Documents
References
[1]. Dave N, et al. Safety and pharmacokinetics of BLU-263, a next-generation KIT inhibitor, in healthy volunteers[C]//Cancer Res (AACR Annual Meeting Abstracts). 2021, 122.
[2]. Mariana Castells, et al. A Phase 2/3 Study of BLU-263 in Patients with Indolent Systemic Mastocytosis or Monoclonal Mast Cell Activation Syndrome. Allergy and Clinical Immunology. 2022, 149 (2).
Same target
Search c-KitSame research area
Search Cancer- BP-00006 SLF Exclusive free base · >98%
- BP-00008 NSC-339004 free base · >98%
- BP-00019 SLF-amido-C2-COOH free base · >98%
- BP-00020 PT262 free base · >98%
- BP-00022 Inolitazone free base · >98%
- BP-00024 KX2-361 free base · >98%
- BP-00030 EML4-ALK kinase inhibitor 1 free base · >98%
- BP-00037 SB 328437 free base · >98%